Coherus craters after Amgen wins reprieve on Neulasta knockoff — FDA rejects marketing application
Shares of Coherus $CHRS tumbled 32% early Monday as news spread that the FDA has rejected its application for a biosimilar of Amgen’s Neulasta. …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.